Market Place
Sourcing Support
Stoke Therapeutics Names Clare Kahn PhD to Its Board of Directors
07 Apr 2026 //
PHARMIWEB
Stoke Therapeutics Awards Inducements Under Nasdaq Rules
17 Mar 2026 //
BUSSINESSWIRE
Stoke Therapeutics to Present at Investor Conferences
28 Aug 2025 //
BUSINESSWIRE
Stoke Therapeutics issues inducement grants per Nasdaq Rule
18 Aug 2025 //
BUSINESSWIRE
Stoke Therapeutics Q2 2025 Financial Results and Business Updates
12 Aug 2025 //
BUSINESSWIRE
Stoke Therapeutics` Webcast on Q2 2025 Business and Updates
07 Aug 2025 //
BUSINESSWIRE
Stoke Therapeutics to Speak at Canaccord Growth Conference
06 Aug 2025 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Rule
16 Jul 2025 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Rule
17 Jun 2025 //
BUSINESSWIRE
Stoke Therapeutics Announces CEO Transition
18 Mar 2025 //
BUSINESSWIRE
Stoke Reports Q4, Full-Year 2024 Results, Business Update
18 Mar 2025 //
BUSINESSWIRE
Stoke Therapeutics Reports Q3 Financial Results & Updates
05 Nov 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Jul 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
03 Jun 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Inducement Grants Under Nasdaq 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Stoke Therapeutics reports first quarter financials and updates.
06 May 2024 //
BUSINESSWIRE
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
29 Apr 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at the 23rd Annual NVH Conference
04 Apr 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
27 Mar 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Proposed Public Offering
26 Mar 2024 //
BUSINESSWIRE
Stoke’s shares up 90% as epilepsy drug cuts convulsive seizures
26 Mar 2024 //
FIERCE BIOTECH
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
25 Mar 2024 //
BUSINESSWIRE
Stoke Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Jan 2024 //
BUSINESSWIRE
Stoke Highlights Strategic Priorities and Anticipated Milestones for 2024
08 Jan 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Stoke Therapeutics Presents Data From Multiple Studies of Children
01 Dec 2023 //
BUSINESSWIRE
Stoke to Present Data from the Company’s Dravet Syndrome Clinical Program
21 Nov 2023 //
BUSINESSWIRE
Stoke Therapeutics Reports Third Quarter Financial Results
07 Nov 2023 //
BUSINESSWIRE
Stoke Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Oct 2023 //
BUSINESSWIRE
Stoke Therapeutics to Participate in 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
BUSINESSWIRE
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
20 Sep 2023 //
BUSINESSWIRE
Stoke Reports Second Quarter Financial Results and Provides Business Updates
07 Aug 2023 //
BUSINESSWIRE
Stoke shares drop 30% as Dravet drug posts high adverse events
25 Jul 2023 //
FIERCE BIOTECH
Stoke Therapeutics Announces Positive Data from Patients Treated with STK-001
25 Jul 2023 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing
16 Jun 2023 //
BUSINESSWIRE
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
03 May 2023 //
BUSINESSWIRE
Stoke Therapeutics Receives Authorization to Initiate a Ph 1/2 Study of STK-002
25 Apr 2023 //
BUSINESSWIRE
FDA partially lifts dosing hold on Stoke`s pediatric Dravet syndrome study
15 Mar 2023 //
ENDPTS
Stoke Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
BUSINESSWIRE
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
27 Feb 2023 //
BUSINESSWIRE
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
BUSINESSWIRE
Stoke Highlights Strategic Priorities and Anticipated Milestones for 2023
09 Jan 2023 //
BUSINESSWIRE
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Ph 1/2a
02 Dec 2022 //
BUSINESSWIRE
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program
29 Nov 2022 //
BUSINESSWIRE
Stoke stumbles on latest interim readout for Dravet syndrome drug
14 Nov 2022 //
FINANCE YAHOO
Stoke Reports Third Quarter Financial Results and Provides Business Updates
14 Nov 2022 //
BUSINESSWIRE
Stoke teases data for possible PhIII dose in lead Dravet syndrome program
14 Nov 2022 //
ENDPTS
Stoke to Host Webinar Call to Present Interim Data Ph1/2a of STK-001
10 Nov 2022 //
BUSINESSWIRE
Stoke Therapeutics Reports Second Quarter Financial Results
08 Aug 2022 //
BUSINESS WIRE
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
BUSINESSWIRE
Stoke Therapeutics Reports First Quarter Financial Results
10 May 2022 //
BUSINESSWIRE
Stoke Therapeutics Presents New In-Vivo Data on STK-002
02 May 2022 //
BUSINESSWIRE
Stoke Therapeutics to Present at ARVO 2022 Annual Meeting
07 Apr 2022 //
BUSINESSWIRE
Stoke Tx Reports Q4 and Full Year 2021 Financial Results
10 Mar 2022 //
BUSINESSWIRE
Stoke Tx to Participate in the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
BUSINESSWIRE
Acadia to Stoke up pipeline with $60M CNS research pact
10 Jan 2022 //
FIERCEBIOTECH
Stoke`s drug, targeting genetic cause of epilepsy, reduces seizure activity
03 Dec 2021 //
STATNEWS
Stoke Announces Presentations from the Company’s Dravet Syndrome
20 Nov 2021 //
BUSINESSWIRE
Stoke Therapeutics Reports Q3 Financial Results, Provides Business Updates
08 Nov 2021 //
BUSINESSWIRE
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
03 Nov 2021 //
BUSINESSWIRE
